Journal: Nature communications
The study investigates why small cell lung cancer (SCLC) is initially chemosensitive yet prone to relapse, and identifies a redox vulnerability that may be exploitable for maintenance therapy.
Key points:
- SCLC cells, like their presumed cells of origin (pulmonary neuroendocrine cells), have intrinsically low activity in pathways that protect against reactive oxygen species (ROS).
- Inhibition of thioredoxin reductase 1 (TXNRD1) rapidly overwhelms the ROS-scavenging capacity of SCLC cells, leading to cytotoxic oxidative stress.
- This vulnerability appears consistent across molecular subtypes of SCLC and is maintained even in cells resistant to first-line therapy, suggesting limited cross-resistance.
- In contrast to non-malignant cells, SCLC cells cannot mount an effective adaptive response to drug-induced ROS. Multiple layers of gene regulation suppress ROS defense mechanisms, preventing metabolic or transcriptional compensation.
- Pharmacologic activation of the NRF2 stress response pathway in vivo selectively boosts antioxidant defenses in normal tissues, allowing escalation of TXNRD1 inhibitor dosing without added systemic toxicity.
- Combining TXNRD1 inhibition with NRF2 activation improves tumor control in preclinical models while sparing healthy tissue.
Overall, the work supports TXNRD1 inhibitors as a rational, biologically targeted approach for SCLC maintenance therapy and suggests that co-activation of NRF2 may widen the therapeutic window by protecting normal cells from oxidative damage.